Ticker League

EBITDA for IDEXX Laboratories (IDXX)

Latest filings through · Reported

Metric

TTM

$1.56B

YoY change

+15.1%

5Y CAGR

+13.1%

Peak year (2025)

$1.47B

EBITDA history chart for IDEXX Laboratories (IDXX) from 1991 to 2025

Latest: $1.47B

EBITDA growth chart for IDEXX Laboratories (IDXX) from 1991 to 2025

Latest: +15.1%

EBITDA history table for IDEXX Laboratories (IDXX) from 1991 to 2025

  • 2025$1.47B+15.1%
  • 2024$1.28B+4.8%
  • 2023$1.22B+20.0%
  • 2022$1.01B-2.4%
  • 2021$1.04B+31.0%
  • 2020$793.81M+23.3%
  • 2019$643.68M+11.8%
  • 2018$575.66M+14.8%
  • 2017$501.42M+16.2%
  • 2016$431.69M+16.6%
  • 2015$370.29M+15.8%
  • 2014$319.81M-0.8%
  • 2013$322.34M+1.9%
  • 2012$316.18M+11.0%
  • 2011$284.75M+13.7%
  • 2010$250.50M+10.7%
  • 2009$226.23M+1.2%
  • 2008$223.59M+26.1%
  • 2007$177.28M+12.4%
  • 2006$157.75M+12.9%
  • 2005$139.70M+10.5%
  • 2004$126.46M+57.3%
  • 2003$80.39M+22.1%
  • 2002$65.81M-16.5%
  • 2001$78.78M+8.3%
  • 2000$72.73M+13.6%
  • 1999$64.00M+41.9%
  • 1998$45.10M+351.0%
  • 1997$10.00M-82.6%
  • 1996$57.40M+48.7%
  • 1995$38.60M+41.4%
  • 1994$27.30M+54.2%
  • 1993$17.70M+105.8%
  • 1992$8.60M+138.9%
  • 1991$3.60M—

EBITDA values are taken from IDEXX Laboratories's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EBITDA at IDEXX Laboratories (IDXX)

According to IDEXX Laboratories's latest reported financial statements, the company's current EBITDA (TTM) is $1.56B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

As of the 2025 fiscal year, IDEXX Laboratories (IDXX) reported EBITDA of $1.47B – grew 15.1% year-over-year.

Through 2020–2025 (5 years), IDEXX Laboratories EBITDA delivered a +13.1% annualised rate; sustaining 3 straight years of year-over-year growth.

Across the available history, EBITDA reached its high of $1.47B in 2025 and its low of $3.60M in 1991.

IDEXX Laboratories EBITDA by Year

IDEXX Laboratories EBITDA 2025: $1.47B

In 2025, IDEXX Laboratories reported EBITDA of $1.47B, grew 15.1% from 2024. This figure represents the highest annual value in the available history.

IDEXX Laboratories EBITDA 2024: $1.28B

IDEXX Laboratories EBITDA in 2024 was $1.28B, edged up 4.8% from 2023.

IDEXX Laboratories EBITDA 2023: $1.22B

2023's EBITDA for IDEXX Laboratories came in at $1.22B, grew 20.0% from 2022.

IDEXX Laboratories EBITDA 2022: $1.01B

IDEXX Laboratories posted EBITDA of $1.01B in 2022, edged down 2.4% below 2021.

IDEXX Laboratories EBITDA 2021: $1.04B

IDEXX Laboratories EBITDA in 2021 was $1.04B.

See more financial history for IDEXX Laboratories (IDXX).

Sector peers by EBITDA

Healthcare peers of IDEXX Laboratories (IDXX), ranked by their latest EBITDA

Frequently asked questions

IDEXX Laboratories (IDXX) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation